Business Wire

Blue Cloud Ventures Expands to Europe With New Office in Berlin

Share

Blue Cloud Management LLC (“Blue Cloud Ventures” or “BCV”), a leading venture capital firm headquartered in New York City, is proud to announce the opening of its European office in Berlin. Blue Cloud Ventures is a growth-stage VC focused on B2B SaaS companies globally. BCV has invested in 43 companies to date, including investments in European companies such as Cognism, Templafy, and most recently, LMS365.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005089/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Blue Cloud Ventures Team (Photo: Business Wire)

With the European tech scene experiencing rapid growth over the past few years, BCV is keen to be part of this emerging ecosystem and partner with founders and investors in the region.

The office will be headed by Victor Yaw, who has been involved in BCV's investments such as Paradox, Trulioo, and Go1, as well as Cognism, Templafy, and LMS365 in Europe.

“We’re thrilled that Victor will be leading our efforts to expand our global footprint; we have been deepening our presence across various regions since raising our fourth fund and see a surge in high-quality B2B SaaS companies being built in Europe,” said Rami Rahal, co-founder and Managing Partner of BCV.

Leveraging its deep U.S. roots, its LP network of 100+ technologists and entrepreneurs globally, and connections across equity and debt funds and service providers, BCV aims to bring a unique set of value-add to European B2B SaaS companies. Through its European presence, BCV will also work closely with its existing portfolio companies in the region, supporting them on their growth journey.

“Since our founding, we have remained focused on being the best partners to our entrepreneurs and their teams,” said Mir Arif, co-founder and Managing Partner of BCV. “We are proud of our readiness to roll up our sleeves and add value, whether by acting as a sounding board to founders, or by assisting with strategy, M&A, recruiting, or customer introductions.”

Berlin was a natural choice for BCV's expansion into Europe, given its status as a tech hub for the region, its location at the heart of the Europe, and its connectivity with other major European cities. The city has a supportive ecosystem for early-stage startups and is quickly emerging as a major hub for companies looking to scale to multi-billion outcomes.

“We are at a key inflection point for B2B SaaS in Europe," said Victor Yaw. "We’ve seen the emergence of a next generation of company builders that have developed the expertise to truly scale to become category-defining platforms. We are excited about our existing investments in the region and believe that this is just the tip of the iceberg."

About Blue Cloud Ventures

Blue Cloud Ventures (BCV) is a software-focused growth stage venture capital fund firm headquartered in New York City. The fund targets investments in leading business applications, infrastructure and open-source software companies. Some of BCV’s past and present portfolio companies include Arctic Wolf Networks, Clari, Cloudbees, Druva, Go1, Iterable, NGINX, Templafy, Pax8 and Wrike. For more information on BCV and our portfolio companies, please visit www.bluecloudventures.com.

Disclaimer - Nothing presented within this article is intended to constitute investment advice, and under no circumstances should any information provided herein be used or considered as an offer to sell or a solicitation of an offer to buy an interest in any investment fund managed by Blue Cloud Management LLC (“Blue Cloud Ventures”). Blue Cloud Ventures does not provide investment advice and is not registered in Germany. Information provided reflects Blue Cloud Ventures’ views as of a time, whereby such views are subject to change at any point and Blue Cloud Ventures shall not be obligated to provide notice of any change. Nothing contained in this article may be relied upon as a guarantee or assurance as to the future success of any particular company. Companies mentioned in this article are a representative sample of portfolio companies in which Blue Cloud Ventures has invested in which the author believes such companies fit the objective criteria stated in commentary, which do not reflect all investments made by Blue Cloud Ventures. Blue Cloud Ventures does not solicit or make its services available to the public and none of the funds are currently open to new investors. While Blue Cloud Ventures has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein, which is subject to change. Past performance is not indicative of future results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victor Yaw: victor@bluecloudventures.com
Julie Hoagland Sorensen: julie@bluecloudventures.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye